Carotid Plaque-Derived Small Extracellular Vesicles Mediate Atherosclerosis and Correlate With Plaque Vulnerability

Abstract

Carotid plaque-derived small extracellular vesicles (psEVs) offer insights into tissue- and disease-specific pathobiology, but their roles in plaque vulnerability and their diagnostic potential remain unclear. Herein, we isolated psEVs from stable and vulnerable (intraplaque hemorrhage [IPH] or fibrous cap rupture [FCR]) plaques in patients with asymptomatic carotid artery stenosis (aCAS). Our findings demonstrated that psEVs alone were sufficient to induce inflammatory endothelial dysfunction in vitro and exacerbate atherogenesis in ApoE-deficient mice. MicroRNA sequencing of psEVs (sequencing cohort, n = 18) identified 21 differentially expressed microRNAs (DEmiRNAs) distinguishing stable and vulnerable plaques, and 41 DEmiRNAs differentiating IPH from FCR subtypes. Subsequent validation using qRT-PCR and the High-throughput nano-bio chip integrated system for liquid biopsy system revealed that plasma-derived sEV miR-497-5p, miR-152-3p, and miR-204-5p effectively differentiated stable plaques from vulnerable plaques, while miR-23a-3p and miR-143-5p further distinguished IPH from FCR subtypes, in both the discovery cohort (n = 178) and an independent external cohort (n = 82). Mechanistic investigations identified miR-497-5p as a key mediator of vulnerable psEVs' proinflammatory and proatherogenic effects through directly targeting atheroprotective uncoupling protein 2 (UCP2). These findings highlight the roles of psEVs in atherogenesis and plaque vulnerability, providing valuable insights for risk stratification and therapeutic decision-making in aCAS patients.

Keywords

asymptomatic carotid artery stenosis / atherosclerosis / biomarker / extracellular vesicle / microRNA / plaque vulnerability

References

[1] R. W. Chang, L. Y. Tucker, K. A. Rothenberg, et al., “Incidence of Ischemic Stroke in Patients With Asymptomatic Severe Carotid Stenosis Without Surgical Intervention,” Jama 327, no. 20 (2022): 1974-1982.

[2] T. Reiff, H. H. Eckstein, U. Mansmann, et al., “Carotid Endarterectomy or Stenting or Best Medical Treatment Alone for Moderate-to-severe Asymptomatic Carotid Artery Stenosis: 5-year Results of a Multicentre, Randomised Controlled Trial,” Lancet Neurology 21, no. 10 (2022): 877-888.

[3] S. Keyhani, E. M. Cheng, K. J. Hoggatt, et al., “Comparative Effectiveness of Carotid Endarterectomy vs Initial Medical Therapy in Patients With Asymptomatic Carotid Stenosis,” JAMA Neurology 77, no. 9 (2020): 1110-1121.

[4] K. I. Paraskevas, M. M. Brown, B. K. Lal, et al., “Recent Advances and Controversial Issues in the Optimal Management of Asymptomatic Carotid Stenosis,” Journal of Vascular Surgery 79, no. 3 (2024): 695-703.

[5] D. P. J. Howard, L. Gaziano, and P. M. Rothwell, “Oxford Vascular S. Risk of Stroke in Relation to Degree of Asymptomatic Carotid Stenosis: A Population-based Cohort Study, Systematic Review, and Meta-analysis,” The Lancet Neurology 20, no. 3 (2021): 193-202.

[6] B. Yang, Y. Ma, T. Wang, et al., “Carotid Endarterectomy and Stenting in a Chinese Population: Safety Outcome of the Revascularization of Extracranial Carotid Artery Stenosis Trial,” Translational Stroke Research 12, no. 2 (2021): 239-247.

[7] D. Bos, B. Arshi, Q. J. A. van den Bouwhuijsen, et al., “Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary Events,” Journal of the American College of Cardiology 77, no. 11 (2021): 1426-1435.

[8] P. Gaba, B. J. Gersh, J. Muller, J. Narula, and G. W. Stone, “Evolving Concepts of the Vulnerable Atherosclerotic Plaque and the Vulnerable Patient: Implications for Patient Care and Future Research,” Nature Reviews Cardiology 20, no. 3 (2023): 181-196.

[9] J. M. Cai, T. S. Hatsukami, M. S. Ferguson, R. Small, N. L. Polissar, and C. Yuan, “Classification of human Carotid Atherosclerotic Lesions With in Vivo Multicontrast Magnetic Resonance Imaging,” Circulation 106, no. 11 (2002): 1368-1373.

[10] L. Saba, R. Cau, A. Murgia, et al., “Carotid Plaque-RADS: A Novel Stroke Risk Classification System,” JACC Cardiovascular Imaging 17, no. 1 (2024): 62-75.

[11] D. Pakizer, J. Kozel, P. Taffe, et al., “Diagnostic Accuracy of Carotid Plaque Instability by Noninvasive Imaging: A Systematic Review and Meta-analysis,” European Heart Journal Cardiovascular Imaging 25, no. 10 (2024): 1325-1335.

[12] H. Khan, F. Shaikh, M. H. Syed, M. Mamdani, G. Saposnik, and M. Qadura, “Current Biomarkers for Carotid Artery Stenosis: A Comprehensive Review of the Literature,” Metabolites 13, no. 8 (2023): 919.

[13] V. Della Corte, F. Todaro, M. Cataldi, and A. Tuttolomondo, “Atherosclerosis and Its Related Laboratory Biomarkers,” International Journal of Molecular Sciences 24, no. 21 (2023): 15546.

[14] J. A. Welsh, D. C. I. Goberdhan, L. O'Driscoll, et al., “Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches,” Journal of Extracellular Vesicles 13, no. 2 (2024): e12404.

[15] G. van Niel, D. R. F. Carter, A. Clayton, D. W. Lambert, G. Raposo, and P. Vader, “Challenges and Directions in Studying Cell-cell Communication by Extracellular Vesicles,” Nature Reviews Molecular Cell Biology 23, no. 5 (2022): 369-382.

[16] S. M. Davidson, C. M. Boulanger, E. Aikawa, et al., “Methods for the Identification and Characterization of Extracellular Vesicles in Cardiovascular Studies: From Exosomes to Microvesicles,” Cardiovascular Research 119, no. 1 (2023): 45-63.

[17] D. Zheng, M. Huo, B. Li, et al., “The Role of Exosomes and Exosomal MicroRNA in Cardiovascular Disease,” Frontiers in Cell and Developmental Biology 8 (2020): 616161.

[18] S. Patel, M. K. Guo, M. Abdul Samad, and K. L. Howe, “Extracellular Vesicles as Biomarkers and Modulators of Atherosclerosis Pathogenesis,” Frontiers in Cardiovascular Medicine 10 (2023): 1202187.

[19] L. Zisser, C. J. Binder, “Extracellular Vesicles as Mediators in Atherosclerotic Cardiovascular Disease,” Journal of Lipid and Atherosclerosis 13, no. 3 (2024): 232-261.

[20] Z. Wehbe, M. Wehbe, A. Al Khatib, et al., “Emerging Understandings of the Role of Exosomes in Atherosclerosis,” Journal of Cellular Physiology (2024): e31454.

[21] F. Buffolo, S. Monticone, G. Camussi, and E. Aikawa, “Role of Extracellular Vesicles in the Pathogenesis of Vascular Damage,” Hypertension 79, no. 5 (2022): 863-873.

[22] J. C. Lee, R. M. Ray, and T. A. Scott, “Prospects and Challenges of Tissue-derived Extracellular Vesicles,” Molecular Therapy: the Journal of the American Society of Gene Therapy 32, no. 9 (2024): 2950-2978.

[23] L. Shen, H. Huang, Z. Wei, et al., “Integrated Transcriptomics, Proteomics, and Functional Analysis to Characterize the Tissue-specific Small Extracellular Vesicle Network of Breast Cancer,” MedComm 4, no. 6 (2023): e433.

[24] M. C. Verwer, J. Mekke, N. Timmerman, et al., “Comparison of Cardiovascular Biomarker Expression in Extracellular Vesicles, Plasma and Carotid Plaque for the Prediction of MACE in CEA Patients,” Scientific Reports 13, no. 1 (2023): 1010.

[25] R. Crescitelli, C. Lasser, and J. Lotvall, “Isolation and Characterization of Extracellular Vesicle Subpopulations From Tissues,” Nature Protocols 16, no. 3 (2021): 1548-1580.

[26] Y. Huang, L. Cheng, A. Turchinovich, et al., “Influence of Species and Processing Parameters on Recovery and Content of Brain Tissue-derived Extracellular Vesicles,” Journal of Extracellular Vesicles 9, no. 1 (2020): 1785746.

[27] S. R. Li, Q. W. Man, X. Gao, et al., “Tissue-derived Extracellular Vesicles in Cancers and Non-Cancer Diseases: Present and Future,” Journal of Extracellular Vesicles 10, no. 14 (2021): e12175.

[28] L. Gan, D. Liu, D. Xie, et al., “Ischemic Heart-Derived Small Extracellular Vesicles Impair Adipocyte Function,” Circulation Research 130, no. 1 (2022): 48-66.

[29] L. Perdomo, X. Vidal-Gomez, R. Soleti, et al., “Large Extracellular Vesicle-Associated Rap1 Accumulates in Atherosclerotic Plaques, Correlates With Vascular Risks and Is Involved in Atherosclerosis,” Circulation Research 127, no. 6 (2020): 747-760.

[30] A. S. Leroyer, H. Isobe, G. Leseche, et al., “Cellular Origins and Thrombogenic Activity of Microparticles Isolated From human Atherosclerotic Plaques,” Journal of the American College of Cardiology 49, no. 7 (2007): 772-777.

[31] A. S. Leroyer, P. E. Rautou, J. S. Silvestre, et al., “CD40 ligand+ Microparticles From human Atherosclerotic Plaques Stimulate Endothelial Proliferation and Angiogenesis a Potential Mechanism for Intraplaque Neovascularization,” Journal of the American College of Cardiology 52, no. 16 (2008): 1302-1311.

[32] P. E. Rautou, A. S. Leroyer, B. Ramkhelawon, et al., “Microparticles From human Atherosclerotic Plaques Promote Endothelial ICAM-1-dependent Monocyte Adhesion and Transendothelial Migration,” Circulation Research 108, no. 3 (2011): 335-343.

[33] M. C. Blaser, F. Buffolo, A. Halu, et al., “Multiomics of Tissue Extracellular Vesicles Identifies Unique Modulators of Atherosclerosis and Calcific Aortic Valve Stenosis,” Circulation 148, no. 8 (2023): 661-678.

[34] M. Peng, R. Sun, Y. Hong, et al., “Extracellular Vesicles Carrying Proinflammatory Factors May Spread Atherosclerosis to Remote Locations,” Cellular and Molecular Life Sciences: CMLS 79, no. 8 (2022): 430.

[35] J. Guo, C. Wu, X. Lin, et al., “Establishment of a Simplified Dichotomic Size-exclusion Chromatography for Isolating Extracellular Vesicles Toward Clinical Applications,” Journal of Extracellular Vesicles 10, no. 11 (2021): e12145.

[36] A. Di Nubila, G. Dilella, R. Simone, and S. S. Barbieri, “Vascular Extracellular Matrix in Atherosclerosis,” International Journal of Molecular Sciences 25, no. 22 (2024): 12017.

[37] S. Guo, L. Wang, K. Cao, et al., “Endothelial NLRP3 Inflammasome Regulation in Atherosclerosis,” Cardiovascular Research (2024).

[38] S. Xu, I. Ilyas, P. J. Little, et al., “Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and beyond: From Mechanism to Pharmacotherapies,” Pharmacological Reviews 73, no. 3 (2021): 924-967.

[39] B. Huang, Z. Zou, Y. Li, et al., “Gasdermin D-Mediated Pyroptosis Promotes the Development of Atherosclerosis,” Laboratory Investigation; a Journal of Technical Methods and Pathology 104, no. 4 (2024): 100337.

[40] P. Li, J. Hong, C. Liang, et al., “Endothelial Cell-released Extracellular Vesicles Trigger Pyroptosis and Vascular Inflammation to Induce Atherosclerosis Through the Delivery of HIF1A-AS2,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 37, no. 6 (2023): e22942.

[41] X. Osteikoetxea, B. Sodar, A. Nemeth, et al., “Differential Detergent Sensitivity of Extracellular Vesicle Subpopulations,” Organic & Biomolecular Chemistry 13, no. 38 (2015): 9775-9782.

[42] T. Li, X. Li, Y. Feng, G. Dong, Y. Wang, and J. Yang, “The Role of Matrix Metalloproteinase-9 in Atherosclerotic Plaque Instability,” Mediators of Inflammation 2020 (2020): 3872367.

[43] S. A. Dabravolski, V. A. Khotina, A. V. Omelchenko, V. A. Kalmykov, and A. N. Orekhov, “The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets,” International Journal of Molecular Sciences 23, no. 2 (2022): 931.

[44] K. Jingushi, M. Uemura, N. Ohnishi, et al., “Extracellular Vesicles Isolated From human Renal Cell Carcinoma Tissues Disrupt Vascular Endothelial Cell Morphology via Azurocidin,” International Journal of Cancer 142, no. 3 (2018): 607-617.

[45] J. Zhou, Z. Wu, J. Hu, et al., “High-throughput Single-EV Liquid Biopsy: Rapid, Simultaneous, and Multiplexed Detection of Nucleic Acids, Proteins, and Their Combinations,” Science Advances 6, no. 47 (2020): eabc1204.

[46] J. Y. Luo, C. K. Cheng, L. He, et al., “Endothelial UCP2 Is a Mechanosensitive Suppressor of Atherosclerosis,” Circulation Research 131, no. 5 (2022): 424-441.

[47] T. J. Van De Parre, W. Martinet, S. Verheye, et al., “Mitochondrial Uncoupling Protein 2 Mediates Temperature Heterogeneity in Atherosclerotic Plaques,” Cardiovascular Research 77, no. 2 (2008): 425-431.

[48] J. Blanc, M. C. Alves-Guerra, B. Esposito, et al., “Protective Role of Uncoupling Protein 2 in Atherosclerosis,” Circulation 107, no. 3 (2003): 388-390.

[49] R. H. Du, F. F. Wu, M. Lu, et al., “Uncoupling Protein 2 Modulation of the NLRP3 Inflammasome in Astrocytes and Its Implications in Depression,” Redox Biology 9 (2016): 178-187.

[50] S. Yang, W. Qin, X. Li, et al., “A Cryostat-based Frozen Section Method to Increase the Yield of Extracellular Vesicles Extracted From Different Tissues,” Biotechniques 73, no. 2 (2022): 90-98.

[51] R. Wei, L. Zhao, G. Kong, et al., “Combination of Size-Exclusion Chromatography and Ultracentrifugation Improves the Proteomic Profiling of Plasma-Derived Small Extracellular Vesicles,” Biological Procedures Online 22 (2020): 12.

[52] N. Karimi, A. Cvjetkovic, S. C. Jang, et al., “Detailed Analysis of the Plasma Extracellular Vesicle Proteome After Separation From Lipoproteins,” Cellular and Molecular Life Sciences: CMLS 75, no. 15 (2018): 2873-2886.

[53] P. D'Acunzo, Y. Kim, J. M. Ungania, R. Perez-Gonzalez, C. N. Goulbourne, and E. Levy, “Isolation of Mitochondria-derived Mitovesicles and Subpopulations of Microvesicles and Exosomes From Brain Tissues,” Nature Protocols 17, no. 11 (2022): 2517-2549.

[54] F. Jansen, X. Yang, S. Proebsting, et al., “MicroRNA Expression in Circulating Microvesicles Predicts Cardiovascular Events in Patients With Coronary Artery Disease,” Journal of the American Heart Association 3, no. 6 (2014): e001249.

[55] X. Chen, S. Chen, J. Pang, et al., “Hepatic Steatosis Aggravates Atherosclerosis via Small Extracellular Vesicle-mediated Inhibition of Cellular Cholesterol Efflux,” Journal of Hepatology 79, no. 6 (2023): 1491-1501.

[56] F. Jiang, Q. Chen, W. Wang, Y. Ling, Y. Yan, and P. Xia, “Hepatocyte-derived Extracellular Vesicles Promote Endothelial Inflammation and Atherogenesis via microRNA-1,” Journal of Hepatology 72, no. 1 (2020): 156-166.

[57] R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp, “Thioredoxin-Interacting Protein Links Oxidative Stress to Inflammasome Activation,” Nature Immunology 11, no. 2 (2010): 136-140.

[58] Z. Shan, C. Yao, Z. L. Li, et al., “Differentially Expressed microRNAs at Different Stages of Atherosclerosis in ApoE-Deficient Mice,” Chinese Medical Journal 126, no. 3 (2013): 515-520.

[59] W. Lu, G. Wan, H. Zhu, T. Zhu, and X. Zhang, “MiR-497-5p Regulates Ox-LDL-Induced Dysfunction in Vascular Endothelial Cells by Targeting VEGFA/p38/MAPK Pathway in Atherosclerosis,” Heliyon 10, no. 7 (2024): e28887.

[60] Z. Zhao, C. Wu, X. He, et al., “miR-152-3p Aggravates Vascular Endothelial Cell Dysfunction by Targeting DEAD-box Helicase 6 (DDX6) Under Hypoxia,” Bioengineered 12, no. 1 (2021): 4899-4910.

[61] R. Ban, C. Huo, J. Wang, G. Zhang, and X. Zhao, “Exploration of the Shared Gene Signatures and Molecular Mechanisms between Ischemic Stroke and Atherosclerosis,” International Journal of General Medicine 17 (2024): 2223-2239.

[62] N. Wang, Y. Yuan, S. Sun, and G. Liu, “microRNA-204-5p Participates in Atherosclerosis via Targeting MMP-9,” Open Medicine 15 (2020): 231-239.

[63] Y. Wu, F. Zhang, R. Lu, et al., “Functional lncRNA-miRNA-mRNA Networks in Rabbit Carotid Atherosclerosis,” Aging 12, no. 3 (2020): 2798-2813.

[64] G. Lu, P. Tian, Y. Zhu, X. Zuo, and X. Li, “LncRNA XIST Knockdown Ameliorates Oxidative Low-density Lipoprotein-induced Endothelial Cells Injury by Targeting miR-204-5p/TLR4,” Journal of Biosciences 45 (2020): 52.

[65] J. Guo, H. Mei, Z. Sheng, Q. Meng, M. M. Veniant, and H. Yin, “Hsa-miRNA-23a-3p Promotes Atherogenesis in a Novel Mouse Model of Atherosclerosis,” Journal of Lipid Research 61, no. 12 (2020): 1764-1775.

[66] K. R. Cordes, N. T. Sheehy, M. P. White, et al., “miR-145 and miR-143 Regulate Smooth Muscle Cell Fate and Plasticity,” Nature 460, no. 7256 (2009): 705-710.

[67] P. Song, Z. Fang, H. Wang, et al., “Global and Regional Prevalence, Burden, and Risk Factors for Carotid Atherosclerosis: A Systematic Review, Meta-analysis, and Modelling Study,” The Lancet Global Health 8, no. 5 (2020): e721-e729.

[68] H. J. Barnett, D. W. Taylor, M. Eliasziw, et al., “Benefit of Carotid Endarterectomy in Patients With Symptomatic Moderate or Severe Stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators,” The New England Journal of Medicine 339, no. 20 (1998): 1415-1425.

[69] B. A. Verhoeven, E. Velema, A. H. Schoneveld, et al., “Athero-express: Differential Atherosclerotic Plaque Expression of mRNA and Protein in Relation to Cardiovascular Events and Patient Characteristics. Rationale and Design,” European Journal of Epidemiology 19, no. 12 (2004): 1127-1133.

[70] J. N. Redgrave, J. K. Lovett, P. J. Gallagher, and P. M. Rothwell, “Histological Assessment of 526 Symptomatic Carotid Plaques in Relation to the Nature and Timing of Ischemic Symptoms: The Oxford Plaque Study,” Circulation 113, no. 19 (2006): 2320-2328.

[71] W. E. Hellings, W. Peeters, F. L. Moll, et al., “Composition of Carotid Atherosclerotic Plaque Is Associated With Cardiovascular Outcome: A Prognostic Study,” Circulation 121, no. 17 (2010): 1941-1950.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.